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Part B: CHAPTER 1 
The role of melatonin in the effective attainment of 
sleep Electroencephalograms (EEG) in children 
LITERATURE REVIEW 
Introduction / background 
The relevance of sleep EEG studies in children: 
Electroencephalogram (EEG) is a useful tool for investigating specific problems of the 
central nervous system in children. In this age group, specifically, it can assist in the 
differentiation between non-epileptic events and epilepsy. For those found to have 
epileptiform activity on their EEGs, it can support a syndromic diagnosis with significant 
management implications for the patient.1 
The state of sleep is often preferred both to avoid artifact and to increase the rate of 
detection of epileptiform discharges in certain types of childhood epilepsies.1 Natural 
sleep is the preferred state and children are routinely sleep deprived prior to EEG 
studies in most centres, including this study’s centre. Performing this procedure in 
children can be challenging, especially in those with intellectual and behavioural 
problems who struggle to keep still, as such, a proportion of children are unable to fall 
asleep without sedatives. 
The use of sleep inducing agents to attain EEG studies in the state of sleep.  
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Many neurophysiological laboratories routinely use pharmacological agents to induce 
sleep, and this often results in distortion of the normal rhythms, such as increase in beta 
activity, thus masking the underlying activity, and or influencing the macrostructure of 
the sleep pattern.2, 3 If an agent to induce sleep must be used then the product should 
be the one with the best efficacy, least side effects and drug interaction profile, and the 
least likelihood of interference with the EEG recording rhythms.   
Chloral hydrate is a pharmacologic agent, commonly used to induce the state of sleep 
in order to perform EEGs, especially as it is considered to have minimal influence on the 
background and epileptiform activity. But there are reports suggesting unpredictable 
alterations in the EEG recordings, with either suppression or exacerbation of 
epileptiform activity, as well as excessive beta activity, or fast rhythms, which can 
obscure the background and mask epileptiform discharges.2, 3 The efficacy of the agent 
as a sedative is well supported with studies reporting between 86-89% successful 
induction of sleep in patients requiring EEGs.2, 4 This agent was one of the primary 
medications used in many units across South Africa, including the centre where the 
current study is based, to induce the state of sleep in children, especially for 
neurophysiological studies. This product is not registered internationally for this use, 
and it was discontinued quite abruptly in South Africa towards the end of 2013.  
Chloral hydrate can have potential adverse side effects. It has an unpleasant taste and 
can induce nausea, vomiting, ataxia, agitation, prolonged sedation, delayed apnea 
events, gastric irritation, potential carcinogenicity and genotoxicity.5, 6 It is 
contraindicated in patients with peptic ulcers, hepatic insufficiency, porphyria, 
respiratory insufficiency, anticoagulant ingestion and hypersensitivity. However during 
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the time that this agent was the primary agent used in many units managing children to 
induce the state of sleep, there were no national reports published that these side 
effects occurred in our population group. National withdrawal of the product occurred, 
on direction by the Medicine Control Council (MCC), when it came to their notice that 
the product was supplied by a Vetinerary medicine producing company, which was not 
licensed to supply to humans. The potential complications noted above remained of 
concern, and led our centre to investigate alternative sleep inducers, rather than 
reverting to import chloral hydrate from a supplier for human subjects, and continuing 
the previous practice of using it. 
The Red Cross War Memorial Children’s Hospital Neurophysiology Unit performs in the 
region of 100 EEG studies a month, about 30-40 of these are sleep studies. Even whilst 
using the chloral hydrate, 1-2 children a month failed to sleep, requiring a rebooked 
appointment or additional “top-up” sedation, a further 2-3 patients a week had inter-
current infections and their studies were deferred since sedation is not given to children 
who are unwell. As a result, for a viable service, which receives referrals from across 
the Western Cape region, and from further afield, to operate, the capacity to perform 
safe and effective sleep EEG studies is essential.   
Following the withdrawal of chloral hydrate at the end of September 2013, an 
alternative agent was explored. Other commonly used agents for sedation, such as 
propofol, benzodiazepines, or barbiturates, influence the EEG recordings and as such 
were not viewed as alternatives for the practice of attaining sleep EEGs.6, 7  
Alternative agents under consideration to replace chloral hydrate, in this setting, were 
dexmedetomidine and melatonin.  
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Dexmedetomidine   is an α2-adrenergic agonist that is approved by the US Food and 
Drug Administration (FDA) for intravenous (IV) administration by continuous infusion for 
up to 24 hours for the sedation of adults during mechanical ventilation in an intensive 
care unit (ICU) setting.8 Dexmedetomidine is thought to work by enhancing an 
endogenous sleep pathway, specifically by decreasing noradrenergic output from the 
locus ceruleus. The agent mimics natural sleep and does not alter the EEG recording as 
dramatically as other sedatives.	Paediatric population studies support efficacy for 
procedural sedation during noninvasive radiologic imaging and EEG.8, 9 The limited 
effects on hemodynamic and respiratory function, may offer some advantages over 
other agents commonly used for EEG sedation.  One of the major limitations however is 
that product data is predominantly based on intravenous and intramuscular routes (IM), 
which are not ideal for paediatric procedures. One recent study supported the IM route 
with good results but this appears unnecessarily invasive if oral alternatives are 
available.10 Buccal dexmedetomidine has 82% bioavailability and is only viable if the 
drug is not swallowed.11 The efficacy of intranasal administration in achieving sedation 
among adult volunteers is reported,12  but this route has not been studied for children. 
Whilst this agent appears to have potential, in our setting the current requirements for 
the agent to be administered under the supervision of an anaesthetist is not realistic and 
the intranasal product untested and expensive. The study site deferred using this 
product based on these significant logistical issues. 
Melatonin (5-Methoxy-N-acetyltryptamine) was the alternate agent considered. It is a 
pineal hormone, whose synthesis is controlled by external factors including 
environmental light. Melatonin regulates sleep–wake cycles through its action on the 
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suprachiasmatic nucleus in the hypothalamus.13, 14 It has been recommended in the 
management of sleep–wake cycle disorders, jet lag, Attention Deficit Hyperactivity 
Disorder (ADHD), autism, visually disturbed children and other sleep disturbances.15-20 
Even add-on therapy for people with epilepsy has been suggested,21, 22 as well as an 
anxiolytic and analgesic in the perioperative period.23 The major side effect of melatonin 
is drowsiness and fatigue, with the main consistent message from studies that the 
substance is safe and well tolerated.16-18, 24-26 Avoidance has been recommended in 
patients with epilepsy, and for people medicated with anticoagulants, based on case 
reports, which have not been substantiated. In relation to the possible exacerbation of 
epilepsy, review of the literature suggests that no firm conclusions can be drawn, but 
that there appears to be no marked overall effect on seizures, neither improvement nor 
worsening.27 The group concluded that there is need for large, well-designed, 
randomised, double-blind, placebo-controlled trials to establish the role of melatonin in 
either predisposing to, or decreasing the likelihood of seizures. The later relates to few 
studies which have examined the potential anticoagulant properties of melatonin.28, 29 
Oral melatonin was found to attenuate the stress-induced elevation in the sensitive 
coagulation activation marker D-dimer without affecting catecholamine activity.28 The 
researchers concluded that this provided preliminary support for a protective effect of 
melatonin in reducing the atherothrombotic risk in patients with acute mental stress. A 
population of healthy adults given a single dose of oral melatonin resulted in with lower 
plasma levels of procoagulant factors 60 minutes later.29 The authors concluded that 
there might be a dose-response relationship between the plasma concentration of 
melatonin and coagulation activity. These studies support that there may be a beneficial 
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anticoagulant effect for patients at risk of artherothromotic conditions, but do not allude 
to the reverse concern of whether use of melatonin could place the patient at risk of 
bleeding tendencies. This issue, relating to avoiding dual prescribing for patients on 
anticoagulation therapy is a logical precaution, but not based on definitive findings of a 
clinical manifestation (excessive bleeding).  The main issue with these indications is that 
the number of studies are few, the consistency and directness limited, and need for 
large randomized controlled studies noted repeatedly.15, 16, 19, 21, 23, 25, 27, 30, 31 Most 
studies are performed using the “over the counter” formulation of melatonin, and as 
such limits the comparison across studies. A few registered formulations exist, including 
a slow release formulation.30, 32, 33 The study by Gringras et al was a double blinded 
randomized placebo controlled phase III trial, which recruited 146 children.25 The group 
noted a negative finding in that the children gained little additional sleep on melatonin, 
but they did report that the melatonin group fell asleep significantly faster. This response 
to melatonin is in-line with the ideal of rapid sleep initiation, in order to perform non-
invasive studies, such as EEG, followed by awakening without the usual sedative 
“hangover” effect. Melatonin has been successfully used to acquire sleep EEGs in 
adults and children in centres overseas.14, 34-38 The reports documented in the next 
section, and summarized in Table 1, illustrate the data which exists – although there are 
limitations with the range in formulations and regimens used and indices measured, the 
consistent conclusion is that melatonin works well for sleep induction for EEG studies 
and is well tolerated. Of note the natural induction of sleep with melatonin, is limited for 
interventions such as MRI, BSAER and VEP, where either the noise, or stimulation, of 
the study is likely to awaken the child from their natural sleep.  
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Review of the literature relating to the role for melatonin and world-wide unit 
practices (Table 1) 
Published studies: Wassmer et al (2001) in 2 almost identical studies reviewed the 
role of melatonin as a sleep inducer for EEG studies.34, 35 The group concluded that 
melatonin could reliably be used for obtaining sleep EEGs in children. They noted that 
the agent was a good alternative to pharmacological sedation and a complementary 
method to sleep deprivation. This was one of the earliest studies supporting a role for 
melatonin as a safe inducer of natural sleep, since then a number of units have made 
this standard policy (see world-wide unit practices below). Ashrafi et al (2010) compared 
melatonin to chloral hydrate for recording sleep EEG in a randomized controlled study 
involving 348 patients.5 They concluded that melatonin was non-toxic in their patient 
group and recommended that a short course of low doses exhibited almost no side 
effects in healthy people. They stated that melatonin was available as a dietary 
supplement without prescription in most countries including the United States and 
Canada. The study by Eisermann et al (2010) found a very good efficacy in sleep 
induction for EEG recording in 70 children (80% efficacy), this included children with 
severe behavioural problems (72% efficacy).33 Sleep duration was, however, short with 
a high proportion of spontaneous arousals but in all patients it was sufficient for EEG 
analysis. For this study the group used the fast-release formulation Circadian® LP. The 
study by Dirani et al compared use of chloral hydrate to attain sleep EEG to a new 
policy of starting with melatonin and only using hydroxine and then chloral hydrate for 
patients who failed to sleep.38 This was a large study and the group found that there 
was a statistically significant reduction in the number of children needing add-on 
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sedation in the melatonin group. They found no difference in the time to sleep and 
duration of sleep between the two groups. They concluded that the use of melatonin 
was safe and highly effective in attaining sleep EEGs and would result in substantial 
reductions in service load. The study by Sander et al reviewed 50 children (27 with 
epilepsy and 23 non-epileptic) they were all sleep deprived and underwent sequential 
random allocation to sleep EEG studies with and without melatonin, such that all 
patients were screened using both modalities but in random order.39 There was no 
effect on the background activity recorded on the EEGs with the addition of melatonin, 
the failure to attain sleep rate was marginally greater in the melatonin group (n=6 versus 
n=2 p = 0.289 ie not statistically significant), and no side effects occurred in the 
melatonin group. In particular, administration of melatonin was found to be very easy 
and was well tolerated by all patients. Gustafsson et al retrospectively reviewed if 
melatonin was as effective as partial sleep deprivation in both inducing sleep and that 
there was no difference in the interictal EEG data recorded.40 They compared 129 EEG 
studies on children administered melatonin, compared to 113 EEGs following partial 
sleep deprivation. They found that melatonin was as effective as partial sleep 
deprivation in inducing sleep and that there was no difference in the capturing of 
interictal EEG discharges. The best results were in the younger children who were less 
than 4 years of age. Fallah et al in a parallel single-blinded randomized clinical trial 
compared the efficacy of melatonin to the intravenous formulation of midazolam given to 
children to attain sleep EEG.41   The group found statistically better success for sleep in 
the melatonin group. Children in the midazolam group suffered more agitation, which 
was transient, and there was no difference in report adverse drug events between 
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interventions. Akaike et al (abstract) retrospectively reviewed their success rates for 
sleep induction in 862 EEGs studies on 523 patients.42 They found that the patients 
administered melatonin achieved sleep more effectively than the control groups given 
CH and or triclofos sodium. They also found that the adverse events were far less in the 
melatonin group. The abstract presentation by Goyal et al supported that melatonin is 
being increasingly used in Clinical Neurophysiology departments worldwide to facilitate 
sleep EEG recordings.36 The authors commented that the use of melatonin in children 
showed a potential to increase the efficiency of the sleep EEG service, which would 
have considerable cost and resource implications for often over-stretched services. This 
last point is of particular relevance to our setting to have an agent that is safe and does 
not have a “hang-over” effect so the children can be discharged timeously would be 
ideal.   
The directness and consistency of these studies was poor, with differing methodologies, 
formulations, definitions of sleep latency and screening tools and as a result comparison 
between them is not reliable. Further the populations studied also varied for the age of 
the children, additional agents prescribed, associated learning or behavioural difficulties 




Table 1: Literature review summary of studies using melatonin for sleep EEGs 
Key CH = chloral hydrate; M= melatonin; RCT = randomized control trial; ADE – adverse drug event NREM – non-rapid 
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Yes (0.5 to 
1.5 years, awake 
< one hour before 
study  
1.5- to 3-years 
defer regular sleep 
time by 2, wake up 
usual time.  
< 3 years reduce 
total sleep time by 
4 hours.) 
2.5 mg liquid 
(1 mg/mL)  




< 5 years  
Recorded percentage of children 
requiring CH top-up from the 
melatonin group.  
Sleep onset latency (stage 2 
sleep) 
EEG recording interictal activity 
Safety 
Efficacy 
Sleep onset latency 
similar CH v M 
Sleep duration also the 
same 
Statistically significant 
reduction in need for 
top-up melatonin group 
(p<0.001) 
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two study 





either had M, 






Yes for the non-
melatonin group 
sleep from 
between 7 p.m. 
and 9 p.m.  
and wake at 4 
a.m. 





5 -16 years 
of age 6 mg, 
15 min prior 
to electrode 
application. 
Occurrence of epileptiform 
discharges 
Number of children who fell 
asleep 
Technical quality of the EEG 
Melatonin was as 
effective as a sleep 
inducer as partial sleep 
deprivation. 
There was no difference 
in interictal discharges 
Older children may have 
performed better with 
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Found statistically better 
success for sleep in the 
melatonin group. 
More agitation 
(transient) in the 
midazolam group 











or received a 
sedative 
hypnotic agent 














































Awoken at 2 or 
3am and kept 







< 7 years 
=5mg 
>7 years 10 
mg 
Patient demographics 
Sleep induction (stage 1) 
Quality and EEG characteristics  
Failures  
n=6 (melatonin group) 
n=2 (isolated sleep deprivation)  
p = 0.289 
Melatonin led of no 
effect on the EEG 
background recording 
Found that melatonin did 
not improve the outcome 





size was small. 















EEGs   
N=348 1/12 – 6 
years 
“uncooperative
” children and 
those referred 
for sleep EEG 
Yes  
(2 hours post 
usual bed-time 





lab ltd, UK) 
2nd dose 
given if no 
sleep at 1 
hour 
Neurological diagnosis 
Sleep onset latency (not 
defined) 
Sleep duration (not defined) 
Drowsiness time (not defined) 
ADE (in first 24 hours post EEG)  
Sleep onset latency 
similar CH v M 
Sleep duration and 
Drowsiness time 
shorter with M 
ADE: diarrhoea n=2 
agitation n=2 
EEG abn 53% M V 46% 
CH (p=0.005) 
Eisermann 

























deprived of sleep 
the night before’)   
5mg capsule 
1-6 yrs = 
5mg 










Sleep latency (from M to stage 2 
NREM sleep) 
Sleep duration  
Telephonic interview 1 week 
after.  
Effective sleep induction 
in 80% of the cohort 
Effective even in 
children with behavioural 
problems (72%)  




No significant ADE  
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2nd dose if 
no sleep 
Wassmer et 
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2.5 mg 




Patient demographics  
Sleep latency (time from “lights 
out” until stage 1NREM sleep) 
Both groups slept 
effectively. 
EEG background was 
not affected by 
melatonin 
Sleep latency was 
significantly shorter in 
the melatonin group 
Wassmer et 
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(mean) 
EEG not affected by M 
No significant ADE 
Minot ADE: headache 
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(n=13); vomited (n=1); 
day 2 seizure (n=2) 
Behaviour of children on 
the study day more 
acceptable to parents in 
the M study group. 
Doesn’t state if this 
group is different or 
includes the same 
patients in the other 
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adults referred 
for EEG 




Found M was more 
effective of all 
interventions inducing 
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No  Not stated Measured successful attainment 
of stage 2 sleep (defined by the 
first 10second epoch containing 
sleep spindles) 
At least 20 minutes of 
stage 2 sleep was 
recorded for all patients. 
Found M to be a good 




Worldwide practice (Table 2): Colleagues on the International Child Neurology 
Association executive board and those on the Pediatric Commission for the 
International League Against Epilepsy where approached. These groups represent 
some of the key opinion leaders in the field of child neurology and are responsible for 
international guidelines relating to epilepsy management in children. They were asked 
two questions.  
1. What agents do they use for sleep EEG studies in their countries / units? 
2. If they have experience with melatonin – whether they have met any issues 
relating to its lack of registration? 
In summary there was an overwhelming response that illustrated that melatonin is 
widely used and accepted in Europe and the States. Whilst the registered slow–release 
version is available in these regions, this has only been considered necessary to use in 
preference to the “over the counter product” in a few settings.   
Table 2: World-wide responses (2013) 
Region Country (personal 





Europe    
 Sweden 
(Prof Orvar Eeg-Oloffson - 
world leading expert in 
epileptology). 
Yes  Use melatonin 3mg tablets 
“with good response” 
 France (Monika Eisermann 
Clinical Neurophysiologist, 
Necker Enfants Malades 
Hospital, Paris Descartes 
University France – lead 
author of the 2010 study) 
Yes Finds melatonin to be very 
helpful and very safe. Now 
use half of the doses, 
means < 6 yrs 5mg, > 6yrs 
10 mg, found it works as 
well as higher doses. 
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Commented that initially 
it was very difficult to 
convince the 
pharmacology 
department to start this 
programme because an 
“authorisation for 
hospital use” was 
difficult to obtain, but 
they managed. This centre 
uses the fast-release 
formulation.  
 Belgium Prof Lieven Legae, 
Head of Paed Neuro, Leuven 




Linda de Meirleir (Head of 
Paediatric Neurology, 










Commented that there are 
numerous papers showing 
efficacy and safety of 
melatonin for sleep 
problems. They often use 
melatonin for autistic and 
blind children, with sleeping 
problems. They have never 
used it as a sedative for 
sleep EEGs as they do 
these EEG's during the 
night. 
This would not be realistic 
in our setting 
 United Kingdom  
(Helen Cross, Prof at Great 
Ormond Street Hospital for 
Sick Children – secretary of 
the ILAE. World leading 
expert in epilepsy) 
Yes  They routinely use it in the 
GOSH unit. Their pharmacy 
coding committee also had 
concerns but accepted the 
“over-the-counter” product 
after motivation. They 
ensure access is from a 
single source, and that it 
can be prescribed.  
 Bulgaria (Petia Dimova, 
Paediatric Neurologist – 
Pediatric Commission ILAE 
member) 
Yes Report excellent results 
with melatonin for EEG. 
Since 2010 it has been 
used instead of Chlorazin, 
and in up to 90% of 
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patients it worked well. 
Occasional add-on 
Chlorpromazin for a few 
patients with severe 
learning difficulties and 
behavioral problems. Have 
data on > 150 children who 
underwent successful sleep 
EEG studies using 
melatonin. There are no 
regulations or standards in 
Bulgaria on how to perform 
EEG in children. They have 
at least 3 different 
formulations of melatonin 
but all are registered as a 
food supplement; so are 
not regarded as "drugs" 
and as such do not fall 
under any regulations. 
 Germany  
(Hans Hartmann, paediatric 
neurologist Pediatric 
Commission ILAE member) 
Yes They have access to a 
commercially available 
melatonin product called 
Circadin. It contains 2 mg / 
prolonged release tablet. it 
is licensed by EMEA  
Asia    
 India 
(Dr. K P Vinayan, Professor 
Division of Pediatric 
Neurology, Amrita Institute of 
Medical Sciences 
Cochin, Kerala; Peds 
Commission ILAE member) 
No Not using Melatonin – they 
have access to triclofos and 
have not been affected by 




   
 United States of America 
(Prof Kenneth Mack, Mayo 
Clinic; ICNA EB) 
 
Yes Use melatonin to attain 
sleep EEGs. It is 
considered a "food additive 
or vitamin" by the FDA, so 
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therefore it is not regulated 
by this body. 
 
 
Transition of the unit to use melatonin and the current study rational 
Left without an alternate sedative agent it was felt, based on the available options, that 
melatonin would be the safest alternative to transfer over to. However beyond other 
centre’s mostly anecdotal opinions (Table 2) and the limited data in the literature (Table 
1),5, 33-36, 38-42 our unit could not be confident that this change in sedation practice would 
be as effective as when chloral hydrate was the first line agent. Also that the patient 
load is still unique to our South African context for socioeconomic and disease 
structures and as such these patients may not respond in the same manner as in the 
published studies. 
From September 2013 our unit changed its standard operating procedure to administer 
melatonin to children who required sleep EEG studies. Since this was a new practice, 
the efficacy was closely monitored, with the aim to review whether it should remain the 
standard operating practice in our unit based on safety, acceptability and efficacy for the 
attainment of sleep EEGs.  
To the best of our knowledge there is no study to determine the use of oral melatonin 
for childhood EEG sleep studies in South Africa or sub-Saharan Africa. This was an 
observational exploratory study, which aimed to determine the safety, acceptability and 
effectiveness of oral melatonin as a natural inducer of sleep to acquire useful EEGs in 
South African children. If shown to be effective this data would assist other centres in 























































































































Part B. Chapter 2. 
The role of melatonin in the effective attainment of Electroencephalograms in 
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Rationale: The paucity of access to electroencephalograms (EEGs) in sub-Saharan 
Africa results in a high patient load attending the few centres with neurophysiology 
units. Sleep state for EEGs performed on children improves yield and reduces 
artefact.  Melatonin induces “natural sleep” without the risk of airway compromise. This 
study evaluated the effectiveness of oral melatonin in attainment of useful 
electroencephalograms in South African children. 
Methods: Consecutive children booked for routine EEG who were either unable to 
cooperate or were referred for sleep EEG received oral melatonin (3mg < 15kg; 6mg > 
15kg) (September 2013-March 2014). Comparison was made to a retrospective control 
group who received the previous sleep protocol agent, chloral hydrate. Outcome 
measures were the proportion of children who achieved sleep, useful EEG study data,  
sleep latency and duration, presence and level of artifacts and presence of recorded 
EEG study abnormalities. 
Results: 173 children were recruited, 88 (51%) male, median age 4 years 9 months 
(interquartile range of 2 years 2 months – 7 years 6 months). 87% of the children 
achieved stage 2 sleep and were deemed to have successfully entered sleep state.  
The median sleep latency was 44.5 minutes and the duration of sleep was 25 minutes 
(range 18.5 – 29 minutes). Children showed no signs of post-sedation irritability or 
persistent drowsiness. They were awoken and were immediately able to go home. In 
the melatonin group there were no adverse events, and no child needed their study 
deferred due to inter-current illnesses. All  children administered melatonin cooperated 
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and permitted a successful EEG recording with useful records even if sleep was not 
achieved. Sedation with melatonin was less successful (74% compared to 88%) in 
children with developmental and behavioural problems (χ 2 = 6.18, P= 0.046), they also 
had higher rate of artifacts (χ 2 = 5.83, P=0.05).  
33.5% of the study group children (n=58) had abnormal EEG studies.  These outcomes 
were comparable to a historical cohort of age equivalent children who were sedated 
with chloral hydrate (45.5%) (χ 2 = 1.22, P= 1.27).  79% that received melatonin 
compared with 86% of those that were sedated with chloral hydrate had artifacts (χ 2 = 
0.63, P= 0.42) 
Conclusion: Melatonin is effective and safe in inducing sleep for EEG recording in our 
setting. 
 











Sleep state is important in performing electroencephalogram in children because it 
reduces the amount of artifacts and can unravel certain epileptiform discharges.1, 2 It is 
also especially useful in young children and those with behavioural and developmental 
challenges because they are unable to lie still for the procedure. Unfortunately most 
sedative medications such as propofol, benzodiazepines and barbiturates affect EEG 
recordings either by distorting background readings or suppressing epileptifiorm 
activities, hence the state of natural sleep is preferred and can be achieved after sleep 
deprivation.3, 4  However, in a proportion of children this can not be achieved and sleep 
inducing medication has to be used.   
Chloral hydrate is the primary agent used in many units managing children to induce the 
state of sleep, especially for neurophysiological studies as it has minimal influence on 
the EEG.5-7  It could however cause persistent sedation after examination leading to 
prolonged observation or even hospitalization; moreover it is not licensed globally and is 
no longer manufactured within South Africa.  
Melatonin (5-Methoxy-N-acetyltryptamine) is a pineal hormone and has been widely used 
to treat sleep disturbances. It has been successfully used to induce sleep EEGs in adults 
and children in centres overseas.8-10 To the best of our knowledge there is no study to 
determine the use of oral melatonin sedation for childhood EEG sleep studies in South 
Africa. This study aims to determine the safety and effectiveness of oral melatonin as 
natural inducer of sleep to acquire useful EEGs in South African children. If shown to be 
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effective this data will assist other centres in South Africa faced with the same challenge 
following the withdrawal of chloral hydrate.   
Aim 
To assess the efficacy, safety and acceptability of melatonin to induce sleep in patients 
for routine sleep state EEG studies in the Neurophysiology unit of Red Cross War 
Memorial Children’s Hospital.  
Objectives: 
Assess the role of melatonin as an effective inducer of sleep for successful attainment 
of EEG by evaluating the impact on the patient outcomes using the following measures: 
1. Sleep onset latency (defined as the duration from full wakefulness to the earliest 
of non-REM stage 2 sleep as recorded on the EEG)11  
2. Sleep duration (the time the child enters non-REM sleep until they are roused at the 
end of the study or they spontaneously awake) 
3. Second dose of sedation, (if no sleep 1 hour post first dose) 
4. Behaviour (agitated, hyperactive, anxious, aggressive) and suspected adverse 
drug events,  
5. Yield in terms of EEG abnormalities – number of abnormal studies, number of 
studies yielding outcomes which will alter patient management 
6. To make recommendations for the regular use of melatonin for sleep studies to 
achieve optimal outcomes for these studies. 
7. To develop a sleep EEG protocol which is effective and viable in our setting and 
can be used across the country.  
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8. To compare the EEG recordings in comparison to a historical group of age 
matched recordings sedated with chloral and to establish if the outcomes 
achieved are in line with the previous unit practice.12  
Methodology 
Study Location 
The study was conducted at the neurophysiology unit of the Paediatric Neurology 
department of the Red Cross War Memorial Children’s Hospital, Rondebosch, Cape 
Town. 
The Neurology department of Red Cross War Memorial Children’s Hospital is a tertiary / 
quaternary referral centre for children with Neurological diseases in the Western Cape. 
EEGs are performed in this unit for both patients managed in the department, referred 
from other internal departments, outside hospitals and the private sector. 
Study Population: These were children who were booked for sleep EEG by the 
referring Physician or were unable to keep still for awake EEG.  
Timing of study: September 2013 –March 2014   
Sleep EEG protocol routinely used in the study site: (Figure 1) 
Sleep deprivation protocol:  All children were encouraged to be sleep deprived prior 
to attending for a sleep EEG. Unit guidelines for children over 3 years of age, 
recommend that the child is kept awake until midnight, is awoken at 4 am and is not 
allowed to sleep between then and the arrival time at the hospital for the EEG.   
Sedation protocol: Once children presented to the department if they had not been 
sleep deprived, appeared unable to keep still and or were unable to fall asleep despite 
being sleep deprived, then the carers were provided with a leaflet to read which advised 
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them of the recommendation to use an agent to induce sleep state (Appendix 1). They 
kept this document as it also addressed possible side effects, during and after, the 
procedure, with a plan of what to do if any of these occured. Before administering the 
agent all carers were spoken to, to ensure that they had no questions and gave 
permission for  the agent to be given to their child. Further the child was examined to 
ensure that they had no evidence of intercurrent illness or evidence of possible airway 
compromise which induced sleep could exacerbate. At the original time of booking the 
referring doctor was also asked if there were any contraindications to the situation 
where their patient may need sedation.  
Standard unit intervention consists of giving melatonin by mouth (3mg for children < 
15kg, 6mg for those > 15kg) 1 hour before the scheduled EEG by the unit nurse. The 
same brand of Melatonin capsules (Swanson®, manufactured by Swanson Health 
Products in the USA) via Equity Pharma was used throughout the study period. Basic 
health checks were maintained throughout the time in the department including the post 
study recovery phase (blood pressure, pulse and respiratory rate). If the child failed to 
fall asleep within one hour of administration of the melatonin then a second dose of 3mg 
was given, assuming that this was convenient for the carer to remain longer in the 
department, if not the patient was re-booked for a further date and the need for effective 
sleep deprivation was reinforced.      
Recording the EEG and data collection  
The EEG was recorded immediately the child fell asleep by the neurophysiologist (LJ). 
EEG surface electrodes were placed on the patients’ head according to the 10/20 
system (standard practice in our unit) and EEG recordings were obtained over 25 -30 
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minutes period.  The calibration was at high-frequency filter of 70 Hz and sensitivity of  
10 uV/mm. The neurophysiologist documented the sleep latency period (defined as the 
duration from taking the medication to stage 2 non-REM sleep as recorded on the 
EEG), whether the child remained adequately asleep for the required period of the 
study, and the observed adverse events into the case record form (CRF) (Appendix 2).  
After the procedure any observed adverse effects were noted while in the hospital (by 
the unit nurse). Parents were encouraged to document any observed adverse event 
within 24 hours and report to LJ.    
The EEGs were evaluated by LJ (Senior Clinical Technologist) and RI (PI) with an aim 
of determining the quality of the records in terms of peak frequency and amplitude on a 
digital monitor at the frontal and parieto-occipital regions of the EEG, both were 
responsible for the assessment and categorization of EEG findings. Quantitative 
assessment of these recordings were based on the system used by Sander et al 9  
grading artefact on a scale 1-5 (1=no artifacts; 2= some, minor artifacts; 3=moderate 
amount of artifacts; 4= substantial artifacts, but EEG recording could be assessed; 
5=unsatisfactory / invalid such that EEG could not be assessed). Overall data was 
reviewed and discussed with JW to ensure consistency and consensus.  LJ is a senior 
clinical neurophysiology technologist who is qualified to report paediatric EEGs. RI is a 
fellow in paediatric neurology training. As part of his curriculum he was trained in EEG 
interpretation by both LJ, the other senior neurophysiology technologist and JW. 
Throughout the study he was supervised by LJ and JW. The reports generated were 
part of the standard outcomes for the unit and as such this data was not specifically 
new. Standard unit practice is to generate reports which include the age and state of the 
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children, and the proposed diagnostic concern. The EEG report itself includes comment 
on specific background rhythms, namely the presence of delta, theta, alpha, beta 
rhythms (including symmetry and region), sleep spindle formation, V waves, and normal 
variants. The presence and extent of artifact is always noted (further if it is physiological 
or non-physiological) and whether it precludes effective reporting i.e. it dominates the 
recording or is minimal to a few pages. Specific abnormalities are documented 
(epileptiform activity, encephalopathic background). Response to hyperventilation and 
intermittent photic stimulation responses, this last aspect was not routinely be 
performed in the study group as their EEG focused on attaining sleep. An overall 
summary of the key findings is documented. The report is then completed with a 
conclusion. 	
For the study purposes additional data was recorded relating to the proportion of a 
recording affected by artifact (graded as listed above 1-5), the quality of the sleep 
recording (the stage reached) and the implications of the findings on the EEG. Normally 
a report is generated which confirms if sleep was attained (with or without sedation), the 
stage of sleep attained, a comment of whether there was artifact is stated (but not the 
extent, unless extreme) and the specific EEG findings which may or may not relate to a 
syndromic diagnosis and a specific treatment intervention. The correlation and 
interpretation of the clinical event and the EEG findings, is not usually undertaken, but 
for the purposes of this study patient records were reviewed to ensure that this data was 
included.   The conclusion may provide outcomes which could alter the management of 
the patient, for example if the EEG pattern was consistent with a recognized syndrome 
such as epileptic spasms, or childhood absence epilepsy. 
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In 2012 a study was completed in the same department which included data on the 
effectiveness of the units previous sedation policy. Whilst chloral hydrate was no longer 
available to form a control arm for this study, the findings and outcomes from this 2012 
study permitted some comparison of efficacy and side effects of the two sedation 
options, namely chloral hydrate compared to melatonin.12 Key areas which both studies 
had comparable data on were the successful completion of the EEG study, whether the 
EEG was normal, abnormal or could not be reported due to excessive artifact, whether 
the EEG was diagnostic of epilepsy, and when the EEG findings altered the actual 
patient management. The final decision on how the findings from the current study 
affected subsequent diagnosis and management were made after review by RI and JW.  
Specific aspects recorded include  
• Whether sleep was attained or not,  
• The sleep latency (time to enter non-REM stage 2 sleep) from when the 
melatonin was given according to Rechchaffen and Kales parameters,11  
• The lack or presence of EEG artifact (an effective enough recording taken to be 
able to generate a useful report),  
• Whether or not abnormalities were recorded and whether this outcome affected 
the patient management (normal study supported a suspected paroxysmal 
disorder, confirmed a diagnosis of benign centro-temporal epilepsy, and so on).  
Recruited children had their demographics recorded such as age, sex, underlying 
aetiology, co-medications, intercurrent infections and co-morbid factors (developmental 
delay, behavioural issues) on case record forms (CRF) [Appendix 2]. Post-study a 
record was kept relating the child’s “return to normal” i.e. how long it took the child to 
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fully awaken, return to previous level of activity and function, also any post discharge 
complaints (all caregivers were encouraged to contact the unit if this occured and they 
attended another unit after hours) and any apparent adverse effects following 24 hours 
after the procedure (excessive sedation, break-through seizures).  
Comparison group: Since supply of choral hydrate was no longer available a direct 
comparison group was not possible between children given chloral against those given 
melatonin. However the study performed the previous year in the department measured 
several parallel and useful outcomes.12  This study addressed the usefulness of 
electroencephalograms in a South African population. A proportion of this group 
screened in 2012 in our unit underwent sleep studies, sedated with chloral (n=22). 
These patients were drawn from the same regional pool, with the same disease 
demographics, and the same sleep deprivation and procedural techniques to the current 
group. This group was screened for several common denominators used in the current 
study, and comparison was made between these, namely the proportion of patients with 
successful attainment of sleep studies, the proportion of studies with excessive artifact 
(precluding interpretation) and the usefulness of the data attained detailing whether the 
studies were able to assist or alter patient management. Whilst the comparison study 
group size was acknowledged to be small, gaining an indication as to whether the 
chloral might have a blunting effect on detection of epileptiform activity was a concern 
and explored as part of the study. As such the proportion of abnormal EEGs was 
compared across groups.  
Data storage and analysis: All data obtained was coded with confidential individual 
number codes (known only to the investigators) and entered into an excel spread sheet 
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with statistical analysis using software from SPSS version 19. to analyse outcomes. 
Means and standard deviations were determined for normally distributed variables, 
while median were determined in non-normally distributed variables, and differences in 
proportions were tested for statistical significance using the chi-square test or Fischer’s 
exact as appropriate. The non-parametric data (comparison between the key outcomes 
of the historical chloral hydrate group versus the melatonin group) was studied using 
Mann-Whitney U tests.  Significance level was set at p< 0.05, with 95% confidence 
level.The computer where the data was located is in a secure part of the 
neurophysiology department.This data was recorded in a secure database only 
accessible to the study personel with patient identifier data coded and names withheld.   
Ethical	issues:	This study was approved by the Faculty of Health Sciences, Research and 
Ethics Committee of the University of Cape Town (Protocol ID 070/2014) and is 
registered with clinical trial.gov ( NCT02195661). This study to the best of our 
knowledge, and as supported by the literature, did not expose the children to any 
unnecessary danger. Melatonin is a natural product and is considered to be generally 
safe. Participants were not paid for participating in the study as their investigation were 
completed as part of standard practice.	
RESULTS MELATONIN 
Demographics 
173 children presented for sleep EEG procedures during the study period (88 males 
and 85 females), the median age of the subjects was 4years 9months ((interquartile 
range of 2years 2months - 7years 6months (age range 0-14 years)) 
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Ninety percent of the referrals were internally generated from within the hospital. The 
emergency department and the Medical outpatient department (MOPD) were the source 
of most of them (Table 1). Most requests for EEGs were from Medical officers and 
General Pediatricians from the MOPD and the emergency department. Referral for EEG 
was based on concern of a diagnosis of epilepsy or to establish if the background 
activity had improved in a patient with established epilepsy.  
One reason for performing sleep EEGs was because the subjects were deemed unlikely 
to cooperate n=73 (42.2%), these included children who were either too young to 
cooperate n=51 (29.5%), had severe intellectual disability n=17 (9.8%) or had 
behavioral problems n=5 (2.9%). The other set of children were those whose previous 
awake records were inconclusive; some had normal recordings in the presence of 
strong clinical suspicion of epilepsy n=31 (17.9%) or abnormal but with either significant 
artifact or the finding was inconsistent with clinical presentation n=13 (7.5%) and or the 
referring physician specifically requested asleep EEG on account of suspicion of 
epileptic seizures with sleep specific EEG findings n=5 (2.9%).  
Sleep outcome (Table 2) 
150 (86.7%) children achieved stage 2 sleep and were deemed to have successfully 
slept, of these 5 required an additional dose of melatonin for them to achieve sleep 
state (a “top-up”). All the subjects including those who did not sleep achieved successful 
EEG recording.  
The median sleep latency was 44.5 minutes, with interquartile range of 30 -67 minutes.  
The median duration of sleep was 25 minutes (range 18.5 – 29 minutes).  
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All the children had no post sedation irritability or persistent drowsiness. They were 
awoken and were immediately able to go home.  
Eleven children had minor upper airway infections but were able to complete their EEG 
studies; in fact no child had their EEG deferred due to inter-current infections. There 
were no recorded adverse events. 
The information of the behavioural/ developmental status of 103 children was 
documented. Thirty-five children had developmental delay and or behavioural problems. 
Twenty-six percent of the children (n=9) with developmental delay and behavioral 
problems did not sleep compared to 12% (n=8) of those without 
developmental/behavioural problems delay  (χ 2 =  6.18, p=0.046).  The age, sex and 
EEG findings did not significantly differ between those who slept and did not sleep 
(Table 3).  
Report of EEG findings 
Background findings 
Since these were sleep records, it was difficult to comment on slowness of background. 
However, 31 records were asymmetric while the remaining records had symmetric 
records. Sleep spindles were noted in all the records of children who successfully slept. 
Artifact 
The recorded artifacts were muscle, movement and electrode artifacts, and excessive 
beta waves. The EEG records of 36 (20.8%) children were free of artifacts.  As shown in 
Figure 2, of the 137 records with artifact 84 (61.3%) and 36 (26.3%) were grades 2 and 
3 artifacts respectively and such such did not preclude reporting the EEGs. 
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More children who slept 32/141 (23%) had no artifacts compared to those that did not 
sleep 0/22 (0.00%) (χ 2=  6.21, P= 0.008).  
33/36 (92%) children with behavioral or developmental problems were statistiacally 
more likely to have artifacts in their records, when compared to those without behavioral 
problems (n=53/70 (76%)). (χ 2=5.83 p=0.05)  
The median sleep latency time of children with artifact in their records was 45 minutes 
(30 -69 minutes) and 43 minutes (29 -59 minutes) for those without artifacts. (z = -1.19, 
p =0.23).  
The median duration of sleep of children with artifacts in their record was 24 minutes 
(range 19 -29 minutes) while it was 26 minutes (range 17 – 30 minutes) for those 
without artifact. (z =1.11, p = 0.27). 
EEG changes 
The EEG records showed that 115 (66.5%) records were normal while 58 (33.5%) 
records were abnormal.  Of the abnormal studies 25 (43.1%) recorded focal discharges, 
31 (53.4%) recorded generalized discharges and 2 (3.4%) had suppression recorded. 
While 33% of (50/98) the children who slept had abnormal EEG recordings, among 
those that did not sleep 30.4% (7/23) had abnormal recordings (χ 2= 0.08, P =0.78).  
Children with abnormal EEGs were not significantly younger than those with normal 
recordings (χ 2 = 3.19, P= 0.20). Among children with behavioural and or developmental 
problems 20/36 (56%) had abnormal EEG recordings. When compared to those without 
developmental and or behavioural problems 19/56 (27.5%) had abnormal EEG record 
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(χ 2 = 7.96, P= 0.006). Other variables including gender were not statistically associated 
with EEG artifacts as shown in Table 4.  
Comparism with the EEG of the Historical group of Patients previously sedated 
with chloral hydrate12  
In a retrospective comparison group of 22 children who were sedated, 21 (95%) 
achieved stage 2 sleep, while artifacts were noted in 19 (86.3%) of them. Of those with 
artifacts 8 (42%) were grade 2 and 11(58%) grade 3. There were no grade 4 or 5 
artifacts noted. There was no statistically significant difference in the amount of artifact 
compared to the melatonin group (79.19%) (χ 2 = 0.63, P= 0.42) 
Ten (45.5%) of the EEG records were abnormal, of these 4 showed generalized 
discharges, 4 focal discharges, one had hypsarrythmia and another generalized slow 
waves. The percentage of EEG abnormality in the melatonin group 58/173 (33.5%) was 
not significantly different when compared to this historical group of children sedated with 
chloral hydrate 10/22 (45.5%) (χ 2 = 1.22, P= 1.27). 
DISCUSSION		
This study supported that melatonin is effective for sleep EEG recording in our setting. 
86% of the children were able to achieve stage 2 sleep with melatonin; this is within the 
limits of 75 – 90% reported in the literature.8, 10, 13-18  It is however interesting to note that 
for all the children a useful EEG record was achieved even among those that did not 
sleep. Despite not sleeping the children were relaxed and calm mainly because some of 
them achieved stage 1 sleep but did not sleep deep enough for sleep spindles to be 
noted and hence were recorded not to have slept.9  
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The previously reported reduced efficacy of pharmacological agents to achieve sleep in 
children with behavioural and learning difficulty as compared to normal children was 
confirmed in the present study.19 In keeping with previous reports melatonin was less 
successful in achieving sedation in children with behavioural and developmental 
problems.  70% of these children successfully achieved sleep compared to 88% of 
those without bahavioural or developmental challenge. The reason for this is not quite 
clear, melatonin is used to achieve sleep in these children.20  However the logistical 
difficulty of achieving sleep deprivation in this class of children may have contributed.17 
Though, it should be noted that these otherwise difficult children remained calm for the 
duration of the EEG even when they did not sleep. 
The median sleep latency was 45 minutes, indeed for all of those who achieved sleep, 
they fell asleep within 69 minutes. The reported median sleep latency/ onset of sleep 
varied between 5 minutes to 45 minutes.9, 10, 21  The reason for this wide difference 
includes the variance in melatonin dosing, differences in application of sleep deprivation 
and subject selection. However, Ashrafiet al8 in their comparison of melatonin and 
chloral hydrate noted that sleep onset time was significantly shorter in the melatonin 
group. The mean duration of sleep in our study was 25 minutes; the children woke up 
easily at the end of the procedure with no post sedation drowsiness, vomiting or “hang 
over” observed. At the end of the procedure they were ready to go home. This finding 
has been previously reported. 13, 21  This made for efficient use of the Neurophysiology 
department as more patients could undergo studies compared to when chloral hydrate 
was used and children had to remain longer while recovering post sedation. 
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Our findings demonstrate that melatonin use for children in an EEG laboratory is safe 
and effective. The induced sleep took effect rapidly and lasted long enough to permit 
electrode application or recording of sleep or both. There was no report of any 
immediate or later complications; this was similar to experiences in other centres.16, 18 
Wassmer et al 10, 13  also did not report any side effects, while Eisermann et al21 and 
Milstein 22 reported only increased sleepiness in a minority of their subjects.  
Sleep state is encourage as it decreases muscle and movement artifacts and improves 
the organization of normal sleep features. However artifacts were reported in 79% of the 
records, this was comparable to the 86% artifact reported from the historical 
comparative group sedated with chloral hydrate previously reported from this centre. 
These artifacts were mainly grades 2 and 3 artifacts that did not affect the readings of 
the EEGs. Sanders et al 9  reported that there was the presence of more artifacts, 52% 
among their melatonin group compared with non-melatonin group 32%, though this 
difference was not statistically significant. The reason for the higher recorded artifact in 
this study compared to the report of Sanders et al is not clear.9 However, we suspect 
that compliance with sleep deprivation was not strictly adhered to by our subjects. 
Melatonin also tends to lead to light sleep with periods of arousal which may account for 
the high artifact rate.23, 24  
Sixty-six percent of the subjects had normal EEG records; this is higher than reported in 
previous studies.9, 13  Comparison is however difficult because of the heterogeneity of 
the sample selection but is comparable to the 62% normal recording reported previously 
from this centre.12  Referrals for EEG in this centre came from different sources. Kander 
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et al observed that inappropriate referral for EEG studies accounted for the majority of 
the non-useful EEG findings.12 
Melatonin has become increasingly popular as a sleep-inducer for both children and 
adults and has been found to be effective even among children with neurological 
abnormalities.20, 25, 26  Among neurophysiology units worldwide, there have been reports 
of its effectiveness in inducing sleep for EEG and the fact that it does not affect the 
sleep structure or the epileptiform discharges.8-10, 16-18, 21, 27  
Study limitations related to the inability to confirm the quality of compliance with sleep 
deprivation. In addition the lack of a parallel control group would have strengthened the 
study, this was not possible as the comparison agent was no longer available at the 
time of the study. So, whilst a control group was identified, using data from the historical 
study, which had recorded comparable variables, this control group size was relatively 
small.  
In summary: This is the first report of the use of melatonin for sleep EEG in children in 
sub–Saharan Africa. Melatonin had no effect on the EEG record and as such did not 
interfere with the EEG reading. Further there was no difference in the proportion of 
studies which recorded interictal epileptiform discharges between the two study group 
and the control group. There were statistically greater artifacts in the children in 
melatonin group with developmental and or behavioural problems, this group was also 
statistically less likely to achieve stage 2 sleep and were the group statistically most 
likely to have abnormalities recorded on their EEG studies. Use of melatonin to achieve 
EEGs in our setting has proved a viable and effective policy change. We feel that the 
transition to using this agent is in-line with facilitating the significant service load, as well 
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Figure 1: Neurophysiology Unit Sleep Policy 
Figure 2: Distribution of artifacts in children sedated with melatonin according to 
grading by Sander et al.9 
Table 1: A  summary of patients’ referral sources (n=173) 
Table 2: Association of sleep outcome and  some variables among children that were 
given melatonin to achieve sleep EEGs   
Table 3: Association between the presence of artifacts and  some variables among 
children that received melatonin to achieve sleep EEG 
Table 4: Association between the presence of abnormal EEG finding and  some 












Figure 1: Neurophysiology Unit Sleep Policy 
Child booked for EEG  
Referring clinician, or staff taking the booking, identify that sleep study required 
Parent advised how to sleep deprive child (over 3 years of age) (stay up until midnight, 
awake at 4am) 
On arrival in the Neurophysiology unit, parent counselled of the study required, time it 
will take, and the need for their child to sleep. 
Policy of using melatonin explained (parents at this stage can request that no agent is 
given but they accept that the child may not cooperate or sleep). 
Child reviewed to document safe to undergo the procedure i.e. no systemic illness, 
airway issues etc. 
Melatonin given 3mg (<15kg) or 6mg (>6mg) 
Child monitored for up to 1 hour (nurse supervised assessment of heart rate and 
respiratory rate)  
Once asleep EEG performed  
If fails to sleep 1 hour after melatonin given – top-up 3mg dose of melatonin given   
If fails still to sleep – study differed, clinician advised and further booking made with 
reattempt at sleep deprivation at a later stage if study still needed 
If study successful – child awoken at end of study, nurse performs basic observations 








Table 1: A  summary of patients’ referral sources (n=173) 
Sources  Frequency Percent 
MOPD 35 29 
emergency 29 24 
NOPD 16 13 
Neurology 10 8. 
development 9 7 
Day hospitals 9 7 
Private practitioners 4 3 
Wards 3 2.5 
Cerebral palsy clinic 3 2.5 
Child psychiatry 2 2 
Genetics 1 1 










Table 2: Association of sleep outcome and  some variables among children that 
were given melatonin to achieve sleep EEGs   
  No sleep 
N=23 
 Sleep   
 N=150 
χ 2 P-value 
Age group (years)     
      < 1 3  9 1.99 0.36 
>1 -5 13 80   
>5 7 61    
Gender     
     Male 11 74  0.02 0.89 
    Female 12  76    
Developmental/behavioural problems     
               Abnormal 9 26    
               Normal 8 60  6.18 0.046 
     
EEG finding                   
             Abnormal 7  50    
             Normal  16 100 0.08 0.78 
     
Artifact      
    Present 23 114 6.75 0.009 





Table 3: Association between the presence of artifacts and  some variables 
among children that received melatonin to achieve sleep EEG 





χ 2 P-value 
Age group (years)     
      < 1 4  8  4.09 0.13 
        >1 -5 22 70   
>5 9 59   
Gender     
     Female 19 66  0.42 0.52 
    Male 17 71   
EEG results     
               Abnormal 14 42   
               Normal 21 95 1.12 0.29 
     
Developmental/behavioural disorders                  
             Abnormal 2 33   








Table 4: Association between the presence of abnormal EEG finding and  some 
variables among children that received melatonin to achieve sleep EEG 








Age group (years)     
      < 1 2 10  3.19 0.20 
        >1-5 28 65   
>5 27 41   
Gender     
    Female 34 51  3.76 0.05 
    Male 23 65   
Developmental/behavioural 
disorders               
    
             Abnormal 19 16   









Figure 2: Distribution of artifacts in children sedated with melatonin according to grading 























Patient / carer information form 
What happens during an EEG study insleep in the department of neurophysiology, Red Cross War 
Memorial Children’s Hospital. 
1 - Why are we giving you this form? 
Some children need to sleep for their EEG test because they are too anxious and or too young to keep 
still on their own. Sometimes the EEG test produces more information when your child is asleep as the 
brain waves can show us more useful activity which may help us to tell whether your child may have, or 
be at risk of having, epilepsy. Unfortunately most of the available medicines which can make your child go 
to sleep interfere with the brain waves readings that we record on the EEG. Chloral Hydrate (50mg/kg) 
and droperidol (0.2mg/kg) are, or have been, the medicines currently used to make children go to sleep. 
These agents all have side effects and can affect the brain waves. Recently supply of chloral hydrate was 
stopped in South Africa.  Melatonin is used in other countries to induce sleep for EEG tests in children. 
We have started to use the same agent in our centre and want to monitor how effective it is for our 
patients. Melatonin is a natural product that is currently used for conditions such as jet lag. It is an “over –
the counter” product, available in most health stores, it is not a prescribed drug.  
2 - Who is monitoring the effectiveness of sleep induction for EEG studies in the department? 
Dr. Roland Ibekwe, Lata Jeave and Professor J Wilmshurst , who are doctors and 
Neurophysiologists  at the Red Cross Memorial Children’s Hospital Rondebosch  
3 - Background Information – monitoring and evaluation of the use of melatonin. 
Your participation is requested because your child needs a sleep EEG test. We will ask you certain 
questions some of which will be personal and also carry out some simple examinations including blood 
pressure, heart beat rate and breathing rate on your child in this regard. The results from this study will 
allow us to improve on how we currently perform sleep EEG studies on children coming to our unit. We 
hope that it will also help other centres in South African who no longer have access to chloral hydrate.  
4 - What Happens In this study 
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Your child will be given our standard dose of melatonin. This drug should help your child sleep within 45 
to 90 minutes. When your childsleeps the technologistwill apply electrodes on your child’s head and 
perform the EEG. This testlasts about25 -45 minutes, after which your child will be woken up, the same 
standard health checks will occur (heart rate, breathing and blood pressure). No needles are used, and 
the leads are fixed to your child’s head through a gel which is completely removed at the end of the study. 
There is no harm from the EEG test itself.  
5 - Possible Problems 
This study to the best of our knowledge would not expose you or your child unnecessarily to any danger. 
Melatonin is a natural product and is considered to be generally safe.Drowsiness extending into the day 
after the study has been described in a few reports. We will not give your child melatonin if he or she is 
taking anti-clotting medicines as there is concern that it could put your child at risk of bleeding.   
6 - Possible Benefits for You and Your Child 
The information that this study provides will allow us to provide better care for children who require sleep 
EEGs in the future.  
7 - Payment 
Neither you nor your child will receive any money for participating in this study.  
8 - Your Rights to Participate, Not Participate, or to Withdraw from the Study 
Taking part in this study is voluntary. If you choose to not have your child participate in this 
study, you and your child will suffer no penalty.  You will not lose any benefits to which you or 
your child is otherwise entitled.  Your child's present or future medical care at the Red Cross 
War Memorial Children’s Hospital will be the same whether or not your child takes part in the 
audit.   
9 - Confidentiality 
Your name and your child's name will never be made public by the investigators. The medical records of 
your child's care will be treated the same as all medical records at the Red Cross War Memorial Children’s 
Hospital  
The information about your child taken during this study, will be identified by a code number to make it very 
difficult for anyone to identify your child. All information will be stored in a secure place. Information from 
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this study and from your child’s medical records may be used for research purposes and may be published 
in the medical literature; however, neither you nor your child's name will be made public by the 
investigators.  
10 - Payment for A Research Related Injury: 
In the event that an unanticipated complication results from a study-related procedure, you should contact 
Dr Roland Ibekwe at Department of Neurology, Red Cross Memorial Children’s Hospital 
Rondebosch(0832430528) or Lata Jeaven at the department of Neurology, Red Cross Memorial 




Appendix 2: Melatonin supplier data (http://www.swansonvitamins.com/swanson-
premium-melatonin-3-mg-120-caps) : The information below is documented by the suppliers 
with the substance melatonin 3mg capsules, 120 tablets.  
• Plays a crucial role in how well we sleep at night 
• Helps control the sleep/wake cycle 
• May help restore normal sleep patterns when you need them 
Control your sleep/wake cycle naturally with the help of Swanson Melatonin! This useful hormone works 
to restore normal sleep patterns while delivering excellent antioxidant support to the body. Each capsule 
supplies 3 mg of melatonin. 
Supplement Facts 
Serving Size 1 Capsule 
		 Amount	Per	Serving	 %	Daily	Value	
Melatonin	 3	mg	 *	
*Daily Value not established. 
Other ingredients: Rice flour, gelatin. 
Suggested Use: As a dietary supplement, take one capsule with water one-half hour before bedtime. 
WARNING: As melatonin may produce drowsiness, do not drive an automobile or operate heavy 
equipment after taking. Do not take this product if you are pregnant or nursing, have an autoimmune 
condition or a depressive disorder, or are under 16 years of age. 
The company states: 
2. Purity & Potency 
Since 2001 Swanson Health Products has voluntarily participated in independent third party Good 
Manufacturing Practices (GMP) audits, long before the FDA released their final regulations for the dietary 
supplement industry. Ingredients are tested at various stages throughout the production process to verify 
purity and potency, and finished products are tested for potency and stability by independent third-party 






CASE REPORT FORM EFFICACY OF MELATONIN IN INDUCING SLEEP 
Identification code    
    
Date of birth    
    
Sex  Male Female 
    
Weight (Kg)    
    
Referral source    
    
    
    
Reason for referral    
    
Medication the child is 
receiving including but 






    
Inter-current illness  Yes No 
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Specify illness    
    
Sleep deprivation  Yes No 
Premedication vital 
sign 
 Blood pressure   Pulse rate 
  Respiratory rate Temperature 
 
    
Time of sleep onset 
(minutes) 
   
    
Duration of sedation 
(minutes) 
   
    
Need for top up 
medication 
 Yes No 
    
Post medication vital 
signs 
 Blood pressure Pulse rate 
  Respiratory rate 
 
Temperature 










Any other observed 
event 
   
Sedation successful  Yes No 
    
 EEG FINDING   
    
Background record   
 
 
    
Artifact  Yes  No 
Type of artifact   
 
 
    
Abnormality  Yes No 
Type of abnormality   
 
 
    
Finding affects 
diagnosis 
 Yes No 
    
  Affects management  Yes  No 















Your Paper Your Way  
 
We now differentiate between the requirements for new and revised submissions. You 
may choose to submit your manuscript as a single Word or PDF file to be used in the 
refereeing process. Only when your paper is at the revision stage, will you be requested 
to put your paper in to a 'correct format' for acceptance and provide the items required 
for the publication of your article. 
To find out more, please visit the Preparation section below. 
 
Types of articles  
 
Seizure - European Journal of Epilepsy publishes the following types of article: 
1.1 Peer-reviewed articles  
a. Full reviews.  
Seizure welcomes comprehensive reviews on all subjects relating to epilepsy and other 
seizure disorders. Authors planning/proposing are invited to discuss their ideas with 
Editor-in-Chief prior to submission. Full reviews should be preceded by an abstract. Full 
reviews should not exceed 7,000 words, include no more than 6 figures or tables and 
150 references. 
b. Focused reviews.  
Seizure is keen to publish focused reviews, especially on the latest developments in 
particular fields or on topics which are currently debated by clinicians and researchers. 
Authors are welcome to approach the Editor-in-Chief with their idea for a focused 
review prior to submission. Focused reviews should be preceded by an abstract. Focused 
reviews should be 1,500-2,500 words, and include no more than 3 figures or tables and 
50 references. 
c. Full-length original research articles.  
The body of the text of these articles should be limited in length to 4,000 words, and 
there should be a maximum of 6 figures or tables. Additional figures, tables and other 
material (such as associated videos) can be submitted as online only Supporting 
Information (see section 'preparation of manuscripts' for further details). Full length 
research articles should be preceded by an abstract. The body of the text of the article 
should be clearly structured into 1) Introduction, 2) Methods 3) Results, 4) Discussion, 
5) Conclusion and 6) References. 
d. Short communications.  
Comprise a number of different kinds of previously unpublished materials including 
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short reports or small case series. Short communications should be preceded by an 
abstract. The body of the text is limited to 1,400 words. There are no more than 12 
references, and 2 figures or tables (combined). 
e. Case reports (Clinical Letters), see also Interactive Case Insights below 
Seizure will also publish particularly instructive case reports in the format of Clinical 
Letters. Clinical Letters will not be preceded by an abstract. The word count is limited to 
1,000 words. Clinical Letters can only include a maximum of 4 references and 2 figures 
or tables (combined), authors may include additional reading as supplementary 
material. 
f. Letters to the Editor  
Letters containing critical assessment of papers recently published in the Seizure - 
European Journal of Epilepsy will be considered for publication in the correspondence 
section. Letters should not exceed 1,000 words including references as necessary, one 
table or one figure. Letters should be typed in double spacing, should have a heading 
and no abbreviations. If related to a previously published article, the article should be 
identified by title, author(s), and volume/page numbers. All letters are subject to 
editorial review. At the Editor's discretion, a letter may be sent to authors of the original 
paper for comment, and both letter and reply may be published together. 
1.2 Editorially-reviewed material  
Other contributions than original research or review articles will be published at the 
discretion of the Editor-in-Chief, with only editorial review. Such material includes: 
obituaries, workshop reports and conference summaries, letters/commentary to the 
Editors (500 word limit, exceptionally including figures or tables), special (brief) reports 
from ILAE Commissions or other working groups, book reviews and announcements. 
 
1.3 Supplements / Special Editions  
The Editor-in-Chief invites ideas for supplements or special editions of Seizure 
including meeting abstracts. Such materials may be published, but only after prior 
arrangement with the Editor-in-Chief. Supplements will incur a charge. The page rate 
for proposed supplements can be negotiated with the Editor-in- Chief. Special editions 
are issues of Seizure wholly or partially dedicated to one particular topic. They may be 
edited or co-edited by internationally recognised experts in their field. Such experts do 
not need to be members of the Editorial Board of Seizure and are welcome to approach 
the Editor-in-Chief with their ideas. Special editions of Seizure would be expected to 
contain the same kind of manuscripts which are published in normal editions. 
Submission checklist  
 
You can use this list to carry out a final check of your submission before you send it to 
the journal for review. Please check the relevant section in this Guide for Authors for 
more details. 
Ensure that the following items are present: 
One author has been designated as the corresponding author with contact details: 
• E-mail address 
• Full postal address 
All necessary files have been uploaded: 
Manuscript: 
• Include keywords 
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• All figures (include relevant captions) 
• All tables (including titles, description, footnotes) 
• Ensure all figure and table citations in the text match the files provided 
• Indicate clearly if color should be used for any figures in print 
Graphical Abstracts / Highlights files (where applicable) 
Supplemental files (where applicable) 
Further considerations 
• Manuscript has been 'spell checked' and 'grammar checked' 
• All references mentioned in the Reference List are cited in the text, and vice versa 
• Permission has been obtained for use of copyrighted material from other sources 
(including the Internet) 
• Relevant declarations of interest have been made 
• Journal policies detailed in this guide have been reviewed 
• Referee suggestions and contact details provided, based on journal requirements 
For further information, visit our Support Center. 
 
Ethics in publishing  
 
Please see our information pages on Ethics in publishing and Ethical guidelines for 
journal publication. 
Declaration of interest  
 
All authors must disclose any financial and personal relationships with other people or 
organizations that could inappropriately influence (bias) their work. Examples of 
potential conflicts of interest include employment, consultancies, stock ownership, 
honoraria, paid expert testimony, patent applications/registrations, and grants or other 
funding. If there are no conflicts of interest then please state this: 'Conflicts of interest: 
none'. More information. 
Submission declaration and verification  
 
Submission of an article implies that the work described has not been published 
previously (except in the form of an abstract or as part of a published lecture or 
academic thesis or as an electronic preprint, see 'Multiple, redundant or concurrent 
publication' section of our ethics policy for more information), that it is not under 
consideration for publication elsewhere, that its publication is approved by all authors 
and tacitly or explicitly by the responsible authorities where the work was carried out, 
and that, if accepted, it will not be published elsewhere in the same form, in English or 
in any other language, including electronically without the written consent of the 
copyright-holder. To verify originality, your article may be checked by the originality 
detection service CrossCheck. 
Changes to authorship  
 
Authors are expected to consider carefully the list and order of 
authors beforesubmitting their manuscript and provide the definitive list of authors at 
the time of the original submission. Any addition, deletion or rearrangement of author 
names in the authorship list should be made only before the manuscript has been 
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accepted and only if approved by the journal Editor. To request such a change, the 
Editor must receive the following from the corresponding author: (a) the reason for 
the change in author list and (b) written confirmation (e-mail, letter) from all authors 
that they agree with the addition, removal or rearrangement. In the case of addition or 
removal of authors, this includes confirmation from the author being added or removed. 
Only in exceptional circumstances will the Editor consider the addition, deletion or 
rearrangement of authors after the manuscript has been accepted. While the Editor 
considers the request, publication of the manuscript will be suspended. If the 
manuscript has already been published in an online issue, any requests approved by the 
Editor will result in a corrigendum. 
Article transfer service  
This journal is part of our Article Transfer Service. This means that if the Editor feels 
your article is more suitable in one of our other participating journals, then you may be 
asked to consider transferring the article to one of those. If you agree, your article will be 
transferred automatically on your behalf with no need to reformat. Please note that your 
article will be reviewed again by the new journal. More information. 
Copyright  
 
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing 
Agreement' (see more information on this). An e-mail will be sent to the corresponding 
author confirming receipt of the manuscript together with a 'Journal Publishing 
Agreement' form or a link to the online version of this agreement. 
Subscribers may reproduce tables of contents or prepare lists of articles including 
abstracts for internal circulation within their institutions. Permission of the Publisher is 
required for resale or distribution outside the institution and for all other derivative 
works, including compilations and translations. If excerpts from other copyrighted 
works are included, the author(s) must obtain written permission from the copyright 
owners and credit the source(s) in the article. Elsevier has preprinted forms for use by 
authors in these cases. 
For open access articles: Upon acceptance of an article, authors will be asked to 
complete an 'Exclusive License Agreement' (more information). Permitted third party 
reuse of open access articles is determined by the author's choice of user license. 
Author rights 
As an author you (or your employer or institution) have certain rights to reuse your 
work. More information. 
Elsevier supports responsible sharing  
Find out how you can share your research published in Elsevier journals. 
Role of the funding source  
 
You are requested to identify who provided financial support for the conduct of the 
research and/or preparation of the article and to briefly describe the role of the 
sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; 
in the writing of the report; and in the decision to submit the article for publication. If 
the funding source(s) had no such involvement then this should be stated. 
Funding body agreements and policies  
Elsevier has established a number of agreements with funding bodies which allow 
authors to comply with their funder's open access policies. Some funding bodies will 
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reimburse the author for the Open Access Publication Fee. Details of existing 
agreements are available online. 
After acceptance, open access papers will be published under a noncommercial license. 
For authors requiring a commercial CC BY license, you can apply after your manuscript 
is accepted for publication. 
Open access  
 
This journal offers authors a choice in publishing their research: 
Open access  
• Articles are freely available to both subscribers and the wider public with permitted 
reuse. 
• An open access publication fee is payable by authors or on their behalf, e.g. by their 
research funder or institution. 
Subscription 
• Articles are made available to subscribers as well as developing countries and patient 
groups through our universal access programs.  
• No open access publication fee payable by authors. 
Regardless of how you choose to publish your article, the journal will apply the same 
peer review criteria and acceptance standards. 
For open access articles, permitted third party (re)use is defined by the 
following Creative Commons user licenses: 
Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)  
For non-commercial purposes, lets others distribute and copy the article, and to include 
in a collective work (such as an anthology), as long as they credit the author(s) and 
provided they do not alter or modify the article. 
 
The open access publication fee for this journal is USD 2200, excluding taxes. Learn 
more about Elsevier's pricing policy: http://www.elsevier.com/openaccesspricing. 
Green open access  
Authors can share their research in a variety of different ways and Elsevier has a 
number of green open access options available. We recommend authors see our green 
open access page for further information. Authors can also self-archive their 
manuscripts immediately and enable public access from their institution's repository 
after an embargo period. This is the version that has been accepted for publication and 
which typically includes author-incorporated changes suggested during submission, 
peer review and in editor-author communications. Embargo period: For subscription 
articles, an appropriate amount of time is needed for journals to deliver value to 
subscribing customers before an article becomes freely available to the public. This is 
the embargo period and it begins from the date the article is formally published online 
in its final and fully citable form. Find out more. 
 
This journal has an embargo period of 12 months. 
Language (usage and editing services)  
Please write your text in good English (American or British usage is accepted, but not a 
mixture of these). Authors who feel their English language manuscript may require 
editing to eliminate possible grammatical or spelling errors and to conform to correct 
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scientific English may wish to use the English Language Editing service available from 
Elsevier's WebShop. 
Informed consent and patient details  
 
Studies on patients or volunteers require ethics committee approval and informed 
consent, which should be documented in the paper. Appropriate consents, permissions 
and releases must be obtained where an author wishes to include case details or other 
personal information or images of patients and any other individuals in an Elsevier 
publication. Written consents must be retained by the author and copies of the consents 
or evidence that such consents have been obtained must be provided to Elsevier on 
request. For more information, please review the Elsevier Policy on the Use of Images or 
Personal Information of Patients or other Individuals. Unless you have written 
permission from the patient (or, where applicable, the next of kin), the personal details 
of any patient included in any part of the article and in any supplementary materials 
(including all illustrations and videos) must be removed before submission. 
Submission  
 
Our online submission system guides you stepwise through the process of entering your 
article details and uploading your files. The system converts your article files to a single 
PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required 
to typeset your article for final publication. All correspondence, including notification of 
the Editor's decision and requests for revision, is sent by e-mail. 
 
Please submit your article via http://ees.elsevier.com/seizure/ 
Referees  
Please submit the names and institutional e-mail addresses of several potential referees. 
For more details, visit our Support site. Note that the editor retains the sole right to 
decide whether or not the suggested reviewers are used. 
 
NEW SUBMISSIONS  
 
Submission to this journal proceeds totally online and you will be guided stepwise 
through the creation and uploading of your files. The system automatically converts 
your files to a single PDF file, which is used in the peer-review process. 
As part of the Your Paper Your Way service, you may choose to submit your manuscript 
as a single file to be used in the refereeing process. This can be a PDF file or a Word 
document, in any format or lay-out that can be used by referees to evaluate your 
manuscript. It should contain high enough quality figures for refereeing. If you prefer to 
do so, you may still provide all or some of the source files at the initial submission. 
Please note that individual figure files larger than 10 MB must be uploaded separately. 
References  
There are no strict requirements on reference formatting at submission. References can 
be in any style or format as long as the style is consistent. Where applicable, author(s) 
name(s), journal title/book title, chapter title/article title, year of publication, volume 
number/book chapter and the pagination must be present. Use of DOI is highly 
encouraged. The reference style used by the journal will be applied to the accepted 
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article by Elsevier at the proof stage. Note that missing data will be highlighted at proof 
stage for the author to correct. 
Formatting requirements  
There are no strict formatting requirements but all manuscripts must contain the 
essential elements needed to convey your manuscript, for example Abstract, Keywords, 
Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with 
Captions. 
If your article includes any Videos and/or other Supplementary material, this should be 
included in your initial submission for peer review purposes. 
Divide the article into clearly defined sections. 
Figures and tables embedded in text  
Please ensure the figures and the tables included in the single file are placed next to the 
relevant text in the manuscript, rather than at the bottom or the top of the file. 
REVISED SUBMISSIONS 
Use of word processing software  
Regardless of the file format of the original submission, at revision you must provide us 
with an editable file of the entire article. Keep the layout of the text as simple as 
possible. Most formatting codes will be removed and replaced on processing the article. 
The electronic text should be prepared in a way very similar to that of conventional 
manuscripts (see also the Guide to Publishing with Elsevier). See also the section on 
Electronic artwork.  
To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 
'grammar-check' functions of your word processor. 
Article structure 
Subdivision - unnumbered sections  
Divide your article into clearly defined sections. Each subsection is given a brief 
heading. Each heading should appear on its own separate line. Subsections should be 
used as much as possible when cross-referencing text: refer to the subsection by heading 
as opposed to simply 'the text'. 
Introduction  
State the objectives of the work and provide an adequate background, avoiding a 
detailed literature survey or a summary of the results. 
Material and methods  
Provide sufficient detail to allow the work to be reproduced. Methods already published 
should be indicated by a reference: only relevant modifications should be described. 
Theory/calculation  
A Theory section should extend, not repeat, the background to the article already dealt 
with in the Introduction and lay the foundation for further work. In contrast, a 
Calculation section represents a practical development from a theoretical basis. 
Results  
Results should be clear and concise. 
 
Only in case of short communications, the results and discussion sections may be 
combined. Results should usually be presented in graphic or tabular form, rather than 
discursively. There should be no duplication in text, tables and figures. Experimental 
conclusions should normally be based on adequate numbers of observations with 
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statistical analysis of variance and the significance of differences. The number of 
individual values represented by a mean should be indicated. 
Discussion  
This should explore the significance of the results of the work, not repeat them. A 
combined Results and Discussion section is often appropriate. Avoid extensive citations 
and discussion of published literature. 
 
Speculative discussion is not discouraged, but the speculation should be based on the 
data presented and identified as such. 
In most cases a discussion of the limitations is appropriate and should be included in 
this section of the manuscript. 
Conclusions  
The main conclusions of the study may be presented in a short Conclusions section, 
which may stand alone or form a subsection of a Discussion or Results and Discussion 
section. 
Appendices  
If there is more than one appendix, they should be identified as A, B, etc. Formulae and 
equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; 
in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table 
A.1; Fig. A.1, etc. 
Essential title page information  
 
• Title. Concise and informative. Titles are often used in information-retrieval systems. 
Avoid abbreviations and formulae where possible. 
• Author names and affiliations. Please clearly indicate the given name(s) and 
family name(s) of each author and check that all names are accurately spelled. Present 
the authors' affiliation addresses (where the actual work was done) below the names. 
Indicate all affiliations with a lower-case superscript letter immediately after the 
author's name and in front of the appropriate address. Provide the full postal address of 
each affiliation, including the country name and, if available, the e-mail address of each 
author. 
• Corresponding author. Clearly indicate who will handle correspondence at all 
stages of refereeing and publication, also post-publication. Ensure that the e-mail 
address is given and that contact details are kept up to date by the 
corresponding author. 
• Present/permanent address. If an author has moved since the work described in 
the article was done, or was visiting at the time, a 'Present address' (or 'Permanent 
address') may be indicated as a footnote to that author's name. The address at which the 
author actually did the work must be retained as the main, affiliation address. 
Superscript Arabic numerals are used for such footnotes. 
Correct author name format  
To prevent confusion please ensure that all author names are listed in the following 
format; first (Christian) name first and the last name (Surname/Family) last. This is 
specified because Spain, China and some other countries often write them differently 





A concise and factual abstract is required. The abstract should state briefly the purpose 
of the research, the principal results and major conclusions. An abstract is often 
presented separately from the article, so it must be able to stand alone. For this reason, 
References should be avoided, but if essential, then cite the author(s) and year(s). Also, 
non-standard or uncommon abbreviations should be avoided, but if essential they must 
be defined at their first mention in the abstract itself. 
 
Abstracts for regular articles and short communications should be structured, using the 
subheadings purpose, methods, results, conclusion. For reviews, the abstract does not 
need to follow this structure. They should be no longer than 250 words. Case reports 
(Clinical Letters) do not need to be preceded by an abstract. 
Graphical abstract  
Although a graphical abstract is optional, its use is encouraged as it draws more 
attention to the online article. The graphical abstract should summarize the contents of 
the article in a concise, pictorial form designed to capture the attention of a wide 
readership. Graphical abstracts should be submitted as a separate file in the online 
submission system. Image size: Please provide an image with a minimum of 531 × 1328 
pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 
cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or 
MS Office files. You can view Example Graphical Abstracts on our information site. 
Authors can make use of Elsevier's Illustration and Enhancement service to ensure the 
best presentation of their images and in accordance with all technical 
requirements: Illustration Service. 
Highlights  
Highlights are mandatory for this journal. They consist of a short collection of bullet 
points that convey the core findings of the article and should be submitted in a separate 
editable file in the online submission system. Please use 'Highlights' in the file name and 
include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). 
You can view example Highlights on our information site. 
 




Immediately after the abstract, provide a maximum of 6 keywords, using British spelling 
and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 
'of'). Be sparing with abbreviations: only abbreviations firmly established in the field 
may be eligible. These keywords will be used for indexing purposes. 
Abbreviations  
Define abbreviations that are not standard in this field in a footnote to be placed on the 
first page of the article. Such abbreviations that are unavoidable in the abstract must be 
defined at their first mention there, as well as in the footnote. Ensure consistency of 
abbreviations throughout the article. 
Acknowledgements  
Collate acknowledgements in a separate section at the end of the article before the 
references and do not, therefore, include them on the title page, as a footnote to the title 
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or otherwise. List here those individuals who provided help during the research (e.g., 
providing language help, writing assistance or proof reading the article, etc.). 
Formatting of funding sources  
List funding sources in this standard way to facilitate compliance to funder's 
requirements: 
Funding: This work was supported by the National Institutes of Health [grant numbers 
xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and 
the United States Institutes of Peace [grant number aaaa]. 
It is not necessary to include detailed descriptions on the program or type of grants and 
awards. When funding is from a block grant or other resources available to a university, 
college, or other research institution, submit the name of the institute or organization 
that provided the funding. 
If no funding has been provided for the research, please include the following sentence: 
This research did not receive any specific grant from funding agencies in the public, 
commercial, or not-for-profit sectors. 
Nomenclature and units  
Follow internationally accepted rules and conventions: use the international system of 
units (SI). If other quantities are mentioned, give their equivalent in SI. You are urged to 
consult IUPAC: Nomenclature of Organic Chemistry for further information. 
Math formulae  
Please submit math equations as editable text and not as images. Present simple 
formulae in line with normal text where possible and use the solidus (/) instead of a 
horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be 
presented in italics. Powers of e are often more conveniently denoted by exp. Number 
consecutively any equations that have to be displayed separately from the text (if 
referred to explicitly in the text). 
Footnotes  
Footnotes should be used sparingly. Number them consecutively throughout the article. 
Many word processors build footnotes into the text, and this feature may be used. 
Should this not be the case, indicate the position of footnotes in the text and present the 
footnotes themselves separately at the end of the article. 
Artwork 
Electronic artwork  
General points 
• Make sure you use uniform lettering and sizing of your original artwork.  
• Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.  
• Number the illustrations according to their sequence in the text.  
• Use a logical naming convention for your artwork files.  
• Indicate per figure if it is a single, 1.5 or 2-column fitting image.  
• For Word submissions only, you may still provide figures and their captions, and 
tables within a single file at the revision stage.  
• Please note that individual figure files larger than 10 MB must be provided in separate 
source files. 
A detailed guide on electronic artwork is available. 
You are urged to visit this site; some excerpts from the detailed information 




Regardless of the application used, when your electronic artwork is finalized, please 
'save as' or convert the images to one of the following formats (note the resolution 
requirements for line drawings, halftones, and line/halftone combinations given 
below):  
EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.  
TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 
300 dpi.  
TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.  
TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum 
of 500 dpi is required.  
Please do not:  
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the 
resolution is too low.  
• Supply files that are too low in resolution.  
• Submit graphics that are disproportionately large for the content. 
Color artwork  
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS 
(or PDF), or MS Office files) and with the correct resolution. If, together with your 
accepted article, you submit usable color figures then Elsevier will ensure, at no 
additional charge, that these figures will appear in color online (e.g., ScienceDirect and 
other sites) regardless of whether or not these illustrations are reproduced in color in 
the printed version. For color reproduction in print, you will receive 
information regarding the costs from Elsevier after receipt of your accepted 
article. Please indicate your preference for color: in print or online only. Further 
information on the preparation of electronic artwork. 
Figure captions  
Ensure that each illustration has a caption. A caption should comprise a brief title 
(not on the figure itself) and a description of the illustration. Keep text in the 
illustrations themselves to a minimum but explain all symbols and abbreviations used. 
Text graphics  
Text graphics may be embedded in the text at the appropriate position. See further 
under Electronic artwork. 
Tables  
 
Please submit tables as editable text and not as images. Tables can be placed either next 
to the relevant text in the article, or on separate page(s) at the end. Number tables 
consecutively in accordance with their appearance in the text and place any table notes 
below the table body. Be sparing in the use of tables and ensure that the data presented 
in them do not duplicate results described elsewhere in the article. Please avoid using 
vertical rules. 
References 
Citation in text  
Please ensure that every reference cited in the text is also present in the reference list 
(and vice versa). Any references cited in the abstract must be given in full. Unpublished 
results and personal communications are not recommended in the reference list, but 
may be mentioned in the text. If these references are included in the reference list they 
should follow the standard reference style of the journal and should include a 
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substitution of the publication date with either 'Unpublished results' or 'Personal 
communication'. Citation of a reference as 'in press' implies that the item has been 
accepted for publication. 
Web references  
As a minimum, the full URL should be given and the date when the reference was last 
accessed. Any further information, if known (DOI, author names, dates, reference to a 
source publication, etc.), should also be given. Web references can be listed separately 
(e.g., after the reference list) under a different heading if desired, or can be included in 
the reference list. 
Data references  
This journal encourages you to cite underlying or relevant datasets in your manuscript 
by citing them in your text and including a data reference in your Reference List. Data 
references should include the following elements: author name(s), dataset title, data 
repository, version (where available), year, and global persistent identifier. Add 
[dataset] immediately before the reference so we can properly identify it as a data 
reference. This identifier will not appear in your published article. 
References in a special issue  
Please ensure that the words 'this issue' are added to any references in the list (and any 
citations in the text) to other articles in the same Special Issue. 
Reference management software  
Most Elsevier journals have their reference template available in many of the most 
popular reference management software products. These include all products that 
support Citation Style Language styles, such as Mendeley and Zotero, as well 
as EndNote. Using the word processor plug-ins from these products, authors only need 
to select the appropriate journal template when preparing their article, after which 
citations and bibliographies will be automatically formatted in the journal's style. If no 
template is yet available for this journal, please follow the format of the sample 
references and citations as shown in this Guide. 
 
Users of Mendeley Desktop can easily install the reference style for this journal by 
clicking the following link: 
http://open.mendeley.com/use-citation-style/seizure-european-journal-of-epilepsy 
When preparing your manuscript, you will then be able to select this style using the 
Mendeley plug-ins for Microsoft Word or LibreOffice. 
Reference formatting  
There are no strict requirements on reference formatting at submission. References can 
be in any style or format as long as the style is consistent. Where applicable, author(s) 
name(s), journal title/book title, chapter title/article title, year of publication, volume 
number/book chapter and the pagination must be present. Use of DOI is highly 
encouraged. The reference style used by the journal will be applied to the accepted 
article by Elsevier at the proof stage. Note that missing data will be highlighted at proof 
stage for the author to correct. If you do wish to format the references yourself they 
should be arranged according to the following examples: 
Reference style  
Text: Indicate references by number(s) in square brackets in line with the text. The 
actual authors can be referred to, but the reference number(s) must always be given.  
List: Number the references (numbers in square brackets) in the list in the order in 
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which they appear in the text.  
Examples:  
Reference to a journal publication:  
[1] Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. J Sci 
Commun 2010;163:51–9.  
Reference to a book:  
[2] Strunk Jr W, White EB. The elements of style. 4th ed. New York: Longman; 2000.  
Reference to a chapter in an edited book:  
[3] Mettam GR, Adams LB. How to prepare an electronic version of your article. In: 
Jones BS, Smith RZ, editors. Introduction to the electronic age, New York: E-Publishing 
Inc; 2009, p. 281–304. 
Reference to a website: 
[4] Cancer Research UK. Cancer statistics reports for the UK, 
http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/; 2003 
[accessed 13.03.03]. 
[dataset] [5] Oguro M, Imahiro S, Saito S, Nakashizuka T. Mortality data for Japanese 
oak wilt disease and surrounding forest compositions, Mendeley Data, v1; 2015. 
http://dx.doi.org/10.17632/xwj98nb39r.1. 
Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors 
the first 6 should be listed followed by 'et al.' For further details you are referred to 
'Uniform Requirements for Manuscripts submitted to Biomedical Journals' (J Am Med 
Assoc 1997;277:927–34) (see also Samples of Formatted References). 
Journal abbreviations source  
Journal names should be abbreviated according to the List of Title Word Abbreviations. 
Video  
 
Elsevier accepts video material and animation sequences to support and enhance your 
scientific research. Authors who have video or animation files that they wish to submit 
with their article are strongly encouraged to include links to these within the body of the 
article. This can be done in the same way as a figure or table by referring to the video or 
animation content and noting in the body text where it should be placed. All submitted 
files should be properly labeled so that they directly relate to the video file's content. In 
order to ensure that your video or animation material is directly usable, please provide 
the files in one of our recommended file formats with a preferred maximum size of 150 
MB. Video and animation files supplied will be published online in the electronic 
version of your article in Elsevier Web products, including ScienceDirect. Please supply 
'stills' with your files: you can choose any frame from the video or animation or make a 
separate image. These will be used instead of standard icons and will personalize the 
link to your video data. For more detailed instructions please visit our video instruction 
pages. Note: since video and animation cannot be embedded in the print version of the 
journal, please provide text for both the electronic and the print version for the portions 
of the article that refer to this content. 
Supplementary material  
 
Supplementary material can support and enhance your scientific research. 
Supplementary files offer the author additional possibilities to publish supporting 
applications, high-resolution images, background datasets, sound clips and more. Please 
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note that such items are published online exactly as they are submitted; there is no 
typesetting involved (supplementary data supplied as an Excel file or as a PowerPoint 
slide will appear as such online). Please submit the material together with the article 
and supply a concise and descriptive caption for each file. If you wish to make any 
changes to supplementary data during any stage of the process, then please make sure to 
provide an updated file, and do not annotate any corrections on a previous version. 
Please also make sure to switch off the 'Track Changes' option in any Microsoft Office 
files as these will appear in the published supplementary file(s). For more detailed 
instructions please visit our artwork instruction pages. 
Database linking  
 
Elsevier encourages authors to connect articles with external databases, giving readers 
access to relevant databases that help to build a better understanding of the described 
research. Please refer to relevant database identifiers using the following format in your 
article: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN). More 
information and a full list of supported databases. 
AudioSlides  
 
The journal encourages authors to create an AudioSlides presentation with their 
published article. AudioSlides are brief, webinar-style presentations that are shown next 
to the online article on ScienceDirect. This gives authors the opportunity to summarize 
their research in their own words and to help readers understand what the paper is 
about. More information and examples are available. Authors of this journal will 
automatically receive an invitation e-mail to create an AudioSlides presentation after 
acceptance of their paper. 
3D neuroimaging  
 
You can enrich your online articles by providing 3D neuroimaging data in NIfTI format. 
This will be visualized for readers using the interactive viewer embedded within your 
article, and will enable them to: browse through available neuroimaging datasets; zoom, 
rotate and pan the 3D brain reconstruction; cut through the volume; change opacity and 
color mapping; switch between 3D and 2D projected views; and download the data. The 
viewer supports both single (.nii) and dual (.hdr and .img) NIfTI file formats. 
Recommended size of a single uncompressed dataset is maximum 150 MB. Multiple 
datasets can be submitted. Each dataset will have to be zipped and uploaded to the 
online submission system via the '3D neuroimaging data' submission category. Please 
provide a short informative description for each dataset by filling in the 'Description' 
field when uploading a dataset. Note: all datasets will be available for downloading from 
the online article on ScienceDirect. If you have concerns about your data being 
downloadable, please provide a video instead. More information. 
Interactive Case Insights  
The journal encourages authors to complement their Clinical Letters with test 
questions that reinforce the key learning points. These author created questions are 
submitted along with the article (new or revised) and will be made available in 
ScienceDirect along with your paper. More information and examples are available 
at http://www.elsevier.com/about/content-innovation/interactive-case-insights. Test 
questions are created online at http://elsevier-
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apps.sciverse.com/GadgetICRWeb/verification. Create the test questions, save them as 
a file to your desktop, and submit along with your (new or revised) manuscript through 
EES. That's it! For questions, please contact icihelp@elsevier.com. 
 
Online proof correction  
 
Corresponding authors will receive an e-mail with a link to our online proofing system, 
allowing annotation and correction of proofs online. The environment is similar to MS 
Word: in addition to editing text, you can also comment on figures/tables and answer 
questions from the Copy Editor. Web-based proofing provides a faster and less error-
prone process by allowing you to directly type your corrections, eliminating the 
potential introduction of errors. 
If preferred, you can still choose to annotate and upload your edits on the PDF version. 
All instructions for proofing will be given in the e-mail we send to authors, including 
alternative methods to the online version and PDF. 
We will do everything possible to get your article published quickly and accurately. 
Please use this proof only for checking the typesetting, editing, completeness and 
correctness of the text, tables and figures. Significant changes to the article as accepted 
for publication will only be considered at this stage with permission from the Editor. It 
is important to ensure that all corrections are sent back to us in one communication. 
Please check carefully before replying, as inclusion of any subsequent corrections cannot 
be guaranteed. Proofreading is solely your responsibility. 
Offprints  
 
The corresponding author will, at no cost, receive 25 free paper offprints, or 
alternatively a customized Share Link providing 50 days free access to the final 
published version of the article on ScienceDirect. The Share Link can be used for sharing 
the article via any communication channel, including email and social media. For an 
extra charge, paper offprints can be ordered via the offprint order form which is sent 
once the article is accepted for publication. Both corresponding and co-authors may 
order offprints at any time via Elsevier's Webshop. Corresponding authors who have 
published their article open access do not receive a Share Link as their final published 
version of the article is available open access on ScienceDirect and can be shared 
through the article DOI link. 
  
 
Visit the Elsevier Support Center to find the answers you need. Here you will find 
everything from Frequently Asked Questions to ways to get in touch. 
You can also check the status of your submitted article or find out when your accepted 
article will be published. 
	
	
